MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Home・Aktien・Microbot Medical Inc

Microbot Medical Inc

Geschlossen

2.12 -0.47

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.07

Max

2.16

Schlüsselkennzahlen
By Trading Economics
Einkommen	-77K -3.6M
Angestellte	20
EBITDA	-79K -3.6M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+299.54% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	23. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.7M 143M
Vorheriger Eröffnungskurs	2.59
Vorheriger Schlusskurs	2.12

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

2.52 / 2.57 Unterstützung & Widerstand

Microbot Medical Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2026, 19:05 UTC

Wichtige Markttreiber

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. Jan. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. Jan. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Jan. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. Jan. 2026, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. Jan. 2026, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. Jan. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. Jan. 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. Jan. 2026, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. Jan. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. Jan. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. Jan. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. Jan. 2026, 19:03 UTC

Ergebnisse

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. Jan. 2026, 18:50 UTC

Ergebnisse

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. Jan. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. Jan. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. Jan. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. Jan. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Peer-Vergleich

Kursveränderung

Microbot Medical Inc Prognose

Kursziel

By TipRanks

299.54% Vorteil

12-Monats-Prognose

Durchschnitt 8.75 USD 299.54%

Hoch 12 USD

Tief 5.5 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Microbot Medical Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Microbot Medical Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

2.52 / 2.57Unterstützung & Widerstand

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bullish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.